Varicella Zoster Infection Treatment Market Size 2022 Global Key Findings, Industry Demand, Regional Analysis, Key Players Profiles, Future Prospects and Forecasts to 2028

The global Varicella Zoster Infection Treatment Market in 2020 is estimated for more than US$ 1.5 Bn and expected to reach a value of US$ 2.0 Bn by 2028 with a significant CAGR of 4.1%. As per Future Market Insights’ projections, in 2022, the acyclovir holds a substantial share of over 55.7% in the overall varicella zoster infection treatment market.

Human alphaherpesvirus 3, also known as Varicella Zoster virus (VZV) is one of the many herpesviruses that is known to infect humans.  It is also the one causing infectious diseases like chicken pox (which is mostly common among children and teens) and herpes zoster (shingles) (mostly affecting adults but rarely in children).  The growing incidence of herpes zoster (shingles) infection among the children’s and the elderly and the rising demand towards the treatment of the infection is aiding the growth of the market.

Request a Sample Report with Table of Contents and Figures

For instance, in December 2016, Slayback and Sandoz signed an agreement with Novartis AG for the sale and marketing rights of Slayback Generic Zovirax Ointment (Acyclovir Ointment). Per the agreement Novartis obtained the sales and marketing rights, which increased their position in the market. Other leading companies operating in the market are Valeant Pharmaceuticals International Inc., Teva Pharmaceutical Industries Ltd, Pfizer Inc., Mylan N.V., Abbott Laboratories, GlaxoSmithKline Plc., and Dr. Reddy’s Laboratories Ltd., among others.

According to the report, the global varicella zoster infection treatment market is expected to register a 4.2% CAGR from 2017 to 2027. In 2016, the market was worth US$ 1,257.1 Mn and is expected to reach a valuation of US$ 1,969.1 Mn by the end of 2027.

Risk of Varicella in Pregnancy and the Need to Adhere to the Guidelines of Chickenpox Treatment to Bode Well for the Market 

Primary infection with varicella zoster in pregnancy may cause maternal mortality or serious morbidity issues. A particular guideline issued in 2015 assesses the evidence regarding maternal and foetal risks of varicella zoster virus infection in pregnancy. The U.K. Advisory Group and Swiss and Canadian national guidelines prescribe procedures for the use of antiviral drugs in pregnancy. The U.K. Advisory Group provides guidelines for chickenpox as well. These guidelines recommend oral acyclovir, which should be prescribed for pregnant women within 24 hours once they present the onset of the rash and if they have 20+0 weeks of gestation or beyond. Guidelines are unanimous nevertheless, in recommending that intravenous acyclovir be administered in cases of severe maternal infection. This factor along with the fact that the rate of exposure and transmission is extremely high in this infection and is a threat for pregnant women and kids, is expected to boost the growth of the varicella zoster infection treatment market.

Our advisory services are aimed at helping you with specific, customised insights that are relevant to your specific challenges. Let us know about your challenges and our trusted advisors will connect with you

Natural Products to Challenge Market Growth

Several people opt for other treatment options for herpes zoster and varicella. These alternative treatment options are expected to hamper the growth of the antiviral drugs market for varicella zoster infection treatment. Homeopathy, supplements, and other natural herbal medicines are used to treat herpes zoster and varicella.

Table Of Content

1. Executive Summary

2. Market Introduction

3. Varicella Zoster Infection Treatment Market Opportunity Analysis 

4. Market Background

5. Global Economic Outlook

6. Key Inclusions

Ask for TOC @

Contact Us:                                                      

Future Market Insights
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries:
For Media Enquiries:

Leave a comment

Your email address will not be published. Required fields are marked *